https://www.pharmacompass.com/ daily 1.00 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sparsentan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levomenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sugemalimab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/r-ketamine-644025 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rimegepant-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-arginine-hydrochloride-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deucravacitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valnemulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mirdametinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/2-4-dichlorobenzyl-alcohol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferric-orthophosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alpha-lipoic-acid-864 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/2-dodecoxyethanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/2-phenoxyethanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/2-phenylphenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/3-5-dibromo-l-tyrosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atogepant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/4-amino-3-phenylbutanoic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/odevixibat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lasofoxifene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/6-methyluracil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/8-quinolinol-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cemdisiran yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-alanine-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abacavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abacavir-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abaloparatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abarelix yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abiraterone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acamprosate-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acarbose yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acebrophylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acebutolol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aceclidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aceclofenac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acemetacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acenocoumarol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acepromazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acetazolamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acetic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acetohydroxamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acetylcholine-chloride-6060 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acetylcysteine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acetyl-l-carnitine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/achillea-millefolium-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/larotrectinib-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acipimox yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acitretin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aclidinium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acotiamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acrivastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acrylic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acyclovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acyclovir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/adapalene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/adefovir-dipivoxil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ademetionine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/adenosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/adenosine-5-monophosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aescin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aesculus-hippocastanum-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/afamelanotide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/afoxolaner yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/agar yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rhenium-186 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/agomelatine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acoramidis-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/albendazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alder-buckthorn yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alectinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alendronate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alendronic-acid-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alfacalcidol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alfaxalone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alfentanil-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alfuzosin-hydrochloride-71764 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aliskiren yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aliskiren-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alitretinoin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alizapride-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/allopurinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/almotriptan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/almotriptan-malate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alogliptin-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aloin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aloxireg yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alpha-terpineol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alprazolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alprostadil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/althaea-officinalis-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/althiazide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/altrenogest yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/altretamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminum-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminum-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminum-magnesium-silicate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alverine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amantadine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amantadine-sulphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ambenonium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ambrisentan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ambroxol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ambroxol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amdinocillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amidotrizoic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amifampridine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amifostine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amikacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amikacin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amiloride-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminacrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminocaproic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminolevulinic-acid-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminolevulinic-acid-hexylester yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminophylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminosalicylic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amiodarone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amiridin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amisulpride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amitraz yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amitriptyline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amitriptyline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amlexanox yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amlodipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amlodipine-besylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amlodipine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ammonia yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ammonium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ammonium-dihydrogen-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ammonium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ammonium-tetrathiomolybdate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosdenopterin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amoxicillin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amoxicillin-trihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amphetamine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amphotericin-b yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ampicillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ampicillin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ampicillin-trihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amprenavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amprolium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amsacrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amtolmetin-guacil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amylmetacresol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anagrelide-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anakinra yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anastrozole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anethole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anethole-trithione yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/angiotensin-ii yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anidulafungin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aniracetam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/antazoline-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apigenin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apixaban yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pegunigalsidase-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apomorphine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apraclonidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apramycin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apremilast yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aprepitant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aprotinin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/arachidonic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/argatroban yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/argatroban-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/arginine-vasopressin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aripiprazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/armodafinil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/arsenic-trioxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/artemether yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/artemisia-absinthium-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/artesunate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/articaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/artichoke yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ascorbic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/asenapine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/asparagine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aspartame yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aspirin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aspirin-lysinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/astemizole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atazanavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atazanavir-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atenolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atipamezole-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atorvastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atosiban yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atovaquone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atracurium-besylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/belladonna-leaf-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atropine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atropine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/attapulgite yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/auranofin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avanafil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avobenzona yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/axitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azacitidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azanidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azaperone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azathioprine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azelaic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azelastine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azithromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azithromycin-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aztreonam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bacampicillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bacitracin-zinc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/baclofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/balsalazide-disodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bambuterol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bamifylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/barium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bazedoxifene-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bcg-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/beclomethasone-dipropionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bedaquiline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benazepril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benazepril-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bendamustine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bendroflumethiazide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benfotiamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benserazide-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzalkonium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzalkonium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzbromarone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levoketoconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzethonium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzhexol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzocaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzododecinium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzoic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzoyl-peroxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzydamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzyl-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzyl-penicillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzylpenicillin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/beta-carotene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betadex yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betahistine-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betamethasone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betamethasone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betamethasone-dipropionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betamethasone-sodium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betamethasone-valerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betaxolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bethanechol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/betula-pendula-roth yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bevacizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bexarotene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bezafibrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bicalutamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bifonazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bilastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bimatoprost yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/biotin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/biperiden-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bisacodyl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bismuth-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bismuth-subcitrate-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bismuth-subgallate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bisoprolol-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bivalirudin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/black-cohosh yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/boceprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/borax-solution yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/boric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bortezomib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bosentan-hydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bosutinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bosutinib-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/boswellia-serrata yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/macrogol-174 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-bromide-hydrate-20553602 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brexpiprazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brimonidine-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brinzolamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brivaracetam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromelain yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromfenac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromfenac-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromhexine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromisoval yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromocriptine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromocriptine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromopride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromperidol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brompheniramine-maleate-5281067 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bronopol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brotizolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/buclizine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/budesonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/buflomedil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bumetanide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bupivacaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bupivacaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/buprenorphine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/buprenorphine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bupropion-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/buserelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/buspirone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/busulfan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/butamirate-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/somapacitan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cabazitaxel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cabergoline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cabozantinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caffeine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caffeine-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcifediol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcipotriol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcitonin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcitriol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-acid-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-ascorbate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-bromolactobionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-chloride-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-dobesilate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-folinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-formate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-ion yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-lactobionate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-pantothenate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-pidolate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-polystyrene-sulfonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-sennoside yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calsil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/camellia-sinensis-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/camphor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/canagliflozin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/candesartan-cilexetil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cangrelor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caninsulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cannabidiol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capecitabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capreomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capsaicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/captopril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caraway yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbachol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbamazepine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbazochrome yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbetapentane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbidopa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbimazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbocisteine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbon-monoxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carboplatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carboprost-tromethamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carboxymethyl-cellulose yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cardamom yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cardura yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carfilzomib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carglumic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cariprazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carisoprodol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carmustine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carteolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carvedilol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cascara yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caspofungin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cassia-senna-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/casticin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/catalase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefaclor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefadroxil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefalotin-sodium-sterile yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefamandole-nafate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefazolin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefazolin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefdinir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefditoren-pivoxil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefepime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefepime-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefixime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefmetazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefminox-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefodizime-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefonicid-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefoperazone-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefotaxime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefoxitin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefoxitin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefpodoxime-proxetil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefprozil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftaroline-fosamil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftazidime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftibuten yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftiofur yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftobiprole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftobiprole-medocaril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftolozane-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceftriaxone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefuroxime-axetil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefuroxime-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/celecoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/celiprolol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cephalexin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cephalexin-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cephalothin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cerazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ceritinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetirizine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetirizine-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetrimide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetrimonium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetrorelix-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetuximab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetylpyridinium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cevimeline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/centella-asiatica-triterpenes yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chenodeoxycholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorambucil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloramphenicol-sodium-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloramphenicol-succinate-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlordiazepoxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlordiazepoxide-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorhexidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorhexidine-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorhexidine-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorhexidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlormadinone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroacetic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorocresol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroprocaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroprocaine-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloropyramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroquine-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroxylenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorpheniramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorpheniramine-maleate-5281068 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorphentermine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorpromazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorpropamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorprothixene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorquinaldol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlortetracycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlortetracycline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorthalidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorzoxazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cholebine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cholestyramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/choline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/choline-alfoscerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/choline-chloride-6209 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/choline-fenofibrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chromic-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chromitope-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cichoric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ciclesonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ciclopirox yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ciclopirox-olamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cidofovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cilastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cilastatin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cilazapril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cilostazol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cimetidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cimetropium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinacalcet-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinchocaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinitapride-hydrogen-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinnamaldehyde yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinnamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinnarizine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinoxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ciprofloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ciprofloxacin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ciprofloxacin-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cisapride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cisatracurium-besylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cisplatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/citalopram yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/citalopram-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/citicoline-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/citric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cladribine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clavulanic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clearine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clebopride-malate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clemastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clenbuterol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clevidipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clidinium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clindamycin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clindamycin-palmitate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clindamycin-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clioquinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clobazam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clobetasol-propionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clobetasone-butyrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clofarabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clofazimine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clomethiazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clomiphene-citrate-3033832 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polyvinyl-alcohol-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clomipramine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clonazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clonidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clopamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloperastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clopidogrel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clopidogrel-besylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clopidogrel-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloprostenol-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clorazepate-dipotassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/closantel-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clotiazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clotrimazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clove-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloxacillin-benzathine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloxacillin-sodium-23675743 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clozapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cobaltous-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cobamamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cobicistat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cobimetinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/codeine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/codeine-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/codliver-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/colchicine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/colesevelam-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/colestipol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/colistimethate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/colistin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/collagenase-clostridium-histolyticum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/collagenase-inhibitor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/conjugated-estrogens yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cortisone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cranberry yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/creatine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/crisaborole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/crizotinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/croscarmellose-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/crotamiton yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cucurbitacin-i yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/curcumin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclizine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclizine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclizine-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclobenzaprine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluphenazine-decanoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclopentolate-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclophosphamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cycloserine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyclosporine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cynara-scolymus-l-folium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyproheptadine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyproterone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cysteamine-bitartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cysteamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cystine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cytarabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cytidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cytisine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dabigatran-etexilate-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dabrafenib-mesylate-44516822 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dacarbazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daclatasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dactinomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dalbavancin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dalda yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dalfopristin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dalteparin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/danazol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dapagliflozin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dapiprazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dapoxetine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dapsone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daptomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/darifenacin-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/darunavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/darunavir-ethanolate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dasabuvir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dasatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daunorubicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/decamethrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/decitabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deferasirox yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deferiprone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deferoxamine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deflazacort yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/degarelix-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/degludec yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dehydroepiandrosterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delapril-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delta-aminolevulinic-acid-methyl-ester yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deltamethrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/demeclocycline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deoxycholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dequalinium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dermatan-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desflurane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desirudin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desloratadine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deslorelin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deslorelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eptacog-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desmopressin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desogestrel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desoxycorticosterone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desvenlafaxine-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/detomidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexamethasone-5743 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexamethasone-sodium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexbrompheniramine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexchloropheniramine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexlansoprazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexmedetomidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexmethylphenidate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexpropranolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexrazoxane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextrans yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextromethorphan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextromethorphan-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextropropoxyphene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextrothyroxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diacerein yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diamorphine-hydrochloride-9844225 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diatrizoate-meglumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diatrizoate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diazoxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dichlorphenamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diclofenac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diclofenac-diethylamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diclofenac-epolamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diclofenac-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diclofenac-sodium-5018304 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dicyclomine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dicyclomine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/didanosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dienogest yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diethyl-ether yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diethylamine-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diethylstilbestrol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diflorasone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diflucortolone-valerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diflunisal yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/digitoxin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/digoxin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroartemisinin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroergocristine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroergocryptine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroergotamine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroergotoxine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydrotachysterol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydrotestosterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroxyaluminium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydroxyaluminum-sodium-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diltiazem yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diltiazem-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimenhydrinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimethicone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimethyl-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimethyl-phthalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimethyl-sulfoxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimetindene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dinoprost-tromethamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dinoprostone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diosmin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dioxidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diphenhydramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diphenhydramine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dipivefrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dipyridamole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/disodium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/disodium-hydrogen-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/disodium-methanehydroxydiphosphonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/disopyramide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/distrontium-renelate-octahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dithranol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ditripental yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/divalproex-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-histidine-monohydrochloride-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-ornithine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-phenylalanine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-proline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-tryptophan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dobutamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/docetaxel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/docosanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/docusate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dodecylnonaglycol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dofetilide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dolutegravir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/domperidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/domperidone-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/donepezil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dopamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doramectin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doripenem yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dorzolamide-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxapram-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxazosin-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxepin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxepin-hydrochloride-6419921 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxofylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxorubicin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxycycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxycycline-hyclate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxycycline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doxylamine-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/d-panthenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dronedarone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/droperidol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/drospirenone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/drotaverine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/droxidopa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dtp-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/duloxetine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dutasteride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dydrogesterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dyphylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ebastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ecallantide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/echinacea-purpurea-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/econazole-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/edaravone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/edotreotide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/edoxaban-tosylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/efavirenz yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eflornithine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/egg-shell-membrane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elbasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eletriptan-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eluxadoline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elvitegravir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emamectin-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emedastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emedastine-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emetine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emodepside yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/empagliflozin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emtricitabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enalapril-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enfuvirtide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enilconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enoxaparin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enoxolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enrofloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/entacapone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/entecavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/entecavir-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enzacamene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enzalutamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ephedrine-9294 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ephedrine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ephedrine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epinephrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epinephrine-bitartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epirubicin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eplerenone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epoprostenol-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eprosartan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eprosartan-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eptifibatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/equisetum-arvense-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erdosteine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ergometrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ergonovine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ergotamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ergotamine-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eribulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erlotinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erlotinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ertapenem yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erythromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erythromycin-estolate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erythromycin-ethyl-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erythromycin-lactobionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erythromycin-stearate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/escitalopram-oxalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/esculin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eslicarbazepine-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/esmolol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/esomeprazole-magnesium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/esomeprazole-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estazolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estradiol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estradiol-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estradiol-valerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estramustine-sodium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estriol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eszopiclone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethacrynic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethambutol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethambutol-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethamsylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethinyl-estradiol-5991 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethionamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethosuximide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethyl-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etidronic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etilefrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etizolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etodolac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etofenamate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etomidate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etonogestrel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etoposide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etoricoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etravirine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eucalyptol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eugenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/evening-primrose-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/everolimus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/exametazime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/exemestane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/exenatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ezetimibe yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ezogabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/famciclovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/famotidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fampridine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/febantel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/febuxostat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/felbamate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/felodipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/felypressin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenbendazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenfluramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenfluramine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenofibrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenoldopam-mesylate-49659 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenoterol-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenpiverinium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fentanyl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fentanyl-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenticonazole-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenugreek yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferric-carboxymaltose yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferric-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferumoxides yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferumoxytol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fesoterodine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fexofenadine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fidaxomicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/finasteride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fingolimod-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/firocoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fish-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flavoxate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flaxseed yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flecainide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flibanserin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/florbetaben yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/florbetapir-f-18 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/florfenicol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/floxacillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flubendazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flucloxacillin-sodium-23667629 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fludarabine-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fludrocortisone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flumazenil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flumethasone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flumethasone-pivalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flunarizine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flunisolide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flunitrazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flunixin-meglumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluocinolone-acetonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluocinonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluocytosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorescein yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorescein-sodium-16850 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorodeoxyglucose-f18 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorometholone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorometholone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorouracil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluoxetine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flupenthixol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flupentixol-decanoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flupentixol-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluphenazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flupirtine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluprednidene-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluralaner-usan-inn yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flurazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flurazepam-monohydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flurbiprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flurbiprofen-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flutamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flutemetamol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluticasone-furoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluticasone-propionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flutrimazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluvastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluvastatin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluvoxamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/folic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fomepizole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fondaparinux-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/formic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/formoterol-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosamprenavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosaprepitant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/foscarnet-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosfomycin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosfomycin-trometamol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosinopril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosphenytoin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/frovatriptan-succinate-hydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/boldine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fucus-vesiculosus-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fulvestrant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fumaria-officinalis-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/furosemide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fusidic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gabapentin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gabexate-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadobenic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadobutrol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadodiamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadofosveset-trisodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadolinium-dtpa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadolinium-ethoxybenzyl-dtpa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadoterate-meglumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadoteridol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadoversetamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/galantamine-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gallium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gallium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gallium-citrate-ga-67-65430 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gallopamil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gamithromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ganciclovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ganciclovir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ganirelix yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/garlic yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gefitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gemcitabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gemfibrozil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gentamicin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gestodene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ginkgo-biloba-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glatiramer-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glibenclamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gliclazide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glimepiride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glipizide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gliquidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucagon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucosamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucosamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucosamine-sulfate-potassium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucose-5793 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glutathione yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glycerine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glycerol-phenylbutyrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glycine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glycopyrronium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glyoxyldiureide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gold-sodium-thiomalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gonadorelin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gonadorelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/goserelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gramicidin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/granisetron yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/granisetron-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/grape-seed-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/grazoprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/green-tea-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/griseofulvin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guaiacol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guaifenesin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guanfacine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guanosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/halcinonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/halofuginone-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/halometasone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/haloperidol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/haloperidol-decanoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/halothane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/harpagophytum-procumbens-dc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/harpagoside yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hawthorn yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivy-leaf yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/helium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hematoporphyrins yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hemin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/heparin-sodium-22833565 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hesperidin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hexamidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hexetidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hexoprenaline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hexyl-nicotinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hexylresorcinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/histidine-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/histrelin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hops-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/human-chorionic-gonadotropin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hyaluronic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hyaluronidase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydralazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydralazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrochlorothiazide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrocortisone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrocortisone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrocortisone-butyrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrocortisone-sodium-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrogen-peroxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydromorphone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroquinone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxocobalamin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxocobalamin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxychloroquine-sulphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxyethyl-starch yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxyprogesterone-caproate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxyurea yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxyzine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hymecromone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hyoscine-butyl-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hyoscyamine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hyperici-herba yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hypericin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vaborbactam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibandronate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibrutinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibuprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibuprofen-lysinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibuprofen-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibutilide-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/icatibant-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/icodextrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/idarubicin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/idebenone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/idelalisib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/idoxuridine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ifosfamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iloprost yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imatinib-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imidacloprid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imipenem yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imipramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imipramine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imiquimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/immunoglobulin-g-285-292 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indacaterol-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indapamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indigo-carmine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indinavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indium-trichloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indium-111 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indobufen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indocyanine-green yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indomethacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ingenol-mebutate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inosine-pranobex yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inositol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-human-recombinant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-aspart yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-detemir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-detemir-recombinant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-glargine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-glulisine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/insulin-lispro yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/interferon-alfa-2b yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/interferon-beta-1a yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iobenguane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iobenguane-sulfate-i-123 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iodinated-glycerol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iodine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iodixanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iodoform yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ioflupane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iohexol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iomeprol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iopamidol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iopromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ioversol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ioxaglic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ipratropium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ipriflavone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/irbesartan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/irinotecan-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iron yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iron-dextran yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iron-sucrose yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isavuconazonium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isocarboxazid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoconazole-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoflurane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoleucine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoniazid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isopropamide-iodide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isopropyl-alcohol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isopropyl-unoprostone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoproterenol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isosorbide-dinitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isosorbide-mononitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isotretinoin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isoxsuprine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isradipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/itopride-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/itraconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivabradine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivabradine-oxalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivermectin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ixazomib-citrate-ester yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/josamycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ginger-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/kaltostat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/kanamycin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enmetazobactam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketanserin-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketazolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketoconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketoprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketorolac-trometamol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketotifen-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/krill-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ks-1200 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/labetalol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lacidipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lacosamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactitol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactobionic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactose-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactose-monohydrate-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactulose yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terlipressin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-alfa-glu-afc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-alpha-lecithin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lamivudine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lamivudine-zidovudine-drug-combination yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lamotrigine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/landiolol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lanreotide-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lansoprazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lanthanum-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lapatinib-ditosylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-arginine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/laropiprant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/latanoprost yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lauromacrogol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-cysteine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ledipasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/leflunomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lenalidomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lenvatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lenvatinib-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lepirudin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lercanidipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lercanidipine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lesinurad yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/letrozole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/leuprolide-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levamisole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levetiracetam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levobunolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levobupivacaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levocabastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levocarnitine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levocetirizine-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levodopa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levodopa-methyl-ester yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levodropropizine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levofloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levofloxacin-hemihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levoleucovorin-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levomenthol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levomepromazine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levonorgestrel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levonorgestrel-oxime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levosimendan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levosulpiride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levothyroxine-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-glutamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-glutamic-acid-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-glutamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-histidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lidocaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lidocaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lifitegrast yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/linaclotide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/linagliptin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lincomycin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/linezolid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/liothyronine-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/liraglutide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lisdexamfetamine-dimesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lisinopril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lithium-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lithium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lixisenatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-lactic-acid-107689 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aspartic-acid-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-glutamic-acid-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-malic-acid-222656 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-methionine-6137 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lodoxamide-tromethamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lomefloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lomitapide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lomustine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loperamide-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lopinavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loracarbef yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loratadine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lorazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lormetazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-ornithine-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-ornithine-l-aspartate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lornoxicam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/losartan-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loteprednol-etabonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lovastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loxapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manidipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-tartaric-acid-444305 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-threonine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lumacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lumefantrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lurasidone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lutein yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lutetium-chloride-lu-177 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-valine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lymecycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lynestrenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lysine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lysine-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lysine-hydrochloride-5962 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/macitentan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magaldrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-acetate-tetrahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-aspartate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-aspartate-tetrahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-chloride-24644 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-hydroxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-lactate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-orotate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-oxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-fluoride-21225527 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-pidolate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/malathion yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/malic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mallow yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mandelic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mangafodipir-trisodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manganese-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manganese-chloride-tetrahydrate-643989 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manganese-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mannitol-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maprotiline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maprotiline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maraviroc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/marbofloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maropitant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/marshmallow-root yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/masitinib-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mebendazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mebeverine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mebrofenin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mecamylamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mechlorethamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meclizine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meclocycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meclofenamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/medazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/medroxyprogesterone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mefenamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mefloquine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/megestrol-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meglumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melatonin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meldonium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melissa-officinalis yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melitracen-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meloxicam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melphalan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melphalan-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/memantine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/menadione yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mentha-piperita-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/menthol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mepenzolate-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meperidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mephobarbital yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mepifiline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mepivacaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mepolizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meprobamate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mequinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mequitazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/merbromin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mercaptopurine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maltodextrin-62698 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meropenem yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mertiatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mesalazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mesna yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meso-2-3-dimercaptosuccinic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mesterolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metacaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metamizole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metaproterenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metformin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methacholine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methacholine-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methacycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methacycline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methadone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methadone-hydrochloride-14184 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methenamine-hippurate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methimazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methionine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methixene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methocarbamol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methotrexate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methoxsalen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methoxyflurane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methscopolamine-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methsuximide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methyl-cellosolve yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methyl-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylcobalamin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methyldopa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylene-blue yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylergonovine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylergonovine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylphenidate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylphenidate-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylprednisolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylprednisolone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylprednisolone-hemisuccinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylprednisolone-sodium-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methysergide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etrasimod-arginine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metipranolol-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metoclopramide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metoclopramide-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metolazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metoprolol-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metoprolol-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metronidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metyrapone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mexiletine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mianserin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/micafungin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/miconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/miconazole-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/midazolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/midazolam-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/midazolam-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/midodrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mifepristone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/miglitol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/miglustat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/milbemycin-oxime yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/miltefosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/minocycline-hydrochloride-54685925 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/minoxidil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mirabegron yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mirtazapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mirtillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/misoprostol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mitomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mitotane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mitoxantrone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mizolastine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moclobemide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/modafinil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moexipril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levomethadone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mometasone-furoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/monensin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/monosodium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/montelukast-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/morniflumate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/morphine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/morphine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moxidectin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moxifloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moxifloxacin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moxonidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mupirocin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mupirocin-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mycophenolate-mofetil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mycophenolate-mofetil-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mycophenolate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mycophenolic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/myroxylon-balsamum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nabumetone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/co-amoxiclav yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/n-acetyl-l-tyrosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/n-acetyltyrosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nadifloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nadolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nafarelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nafronyl-oxalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naftifine-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nalbuphine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nalmefene-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naloxegol-oxalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naloxone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naltrexone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naltrexone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naltrexone-methobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nandrolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nandrolone-decanoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naphazoline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naphazoline-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naproxen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naproxen-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naratriptan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naratriptan-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nateglinide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dota yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfanilic-acid-8479 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nebivolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nedocromil-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nedocromilo yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nefopam-hydrochloride-155290 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nelarabine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nelfinavir-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/neomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/neomycin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/neostigmine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/neostigmine-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/neostigmine-methylsulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nepafenac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/netilmicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/netupitant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nevirapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/niacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/niacinamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nicardipine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nicergoline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/niclosamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nicorandil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nicotine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nifedipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/niflumic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nifuratel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nifuroxazide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nilotinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nilutamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nimesulide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nimodipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nintedanib-esylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nisoldipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitenpyram yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitisinone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitrazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitrendipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitric-oxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitrofurantoin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitrofurazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitrogen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitroglycerin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ephedrine-hydrochloride-71290 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nitrous-oxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nizatidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nomegestrol-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nonivamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nonoxynol-9 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nordazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norepinephrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norepinephrine-bitartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norethisterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norethisterone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norfloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norgestimate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norprolac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nortriptyline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/noscapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/noscapine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daridorexant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/finerenone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nystatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/obeticholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/octenidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/octreotide-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ofatumumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ofloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olanzapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olaparib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olmesartan-medoxomil-130881 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olodaterol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olopatadine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olsalazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ombitasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omega-3 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omeprazole-4594 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omeprazole-magnesium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omeprazole-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ondansetron yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ondansetron-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/opaliferin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/opipramol-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orbifloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oritavancin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oritavancin-diphosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orlistat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ornidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ornithine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orphenadrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orphenadrine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orthosiphon-stamineus-benth yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oseltamivir-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/osimertinib-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ospemifene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oteracil-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/otilonium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxacillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxalic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxaliplatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxaprozin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxatomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxcarbazepine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxeladin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxiconazole-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxolinic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxprenolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxybuprocaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxybutynin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxybutynin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxycodone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxygen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxymetazoline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxytetracycline-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxytetracycline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxytocin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ozenoxacin-jan-inn yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ozogamicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/p-829 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paclitaxel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/palbociclib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paliperidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paliperidone-palmitate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/palonosetron yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pancreatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pancuronium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/panobinostat-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pantethine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pantoprazole-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fostemsavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pantothenic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/papain yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/papaverine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paracetamol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/parecoxib-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paricalcitol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paritaprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paromomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paromomycin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paroxetine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paroxetine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pasireotide-diaspartate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pasireotide-pamoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/passiflora-incarnata-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/passion-flower yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pazopanib-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pectin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pefloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pegfilgrastim yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pelargonium-sidoides yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pemetrexed yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pemetrexed-disodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penciclovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillin-g-benzathine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillin-g-potassium-23664709 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillin-g-procaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillin-v yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillin-v-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentaerythritol-tetranitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentamidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentamidine-isethionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentazocine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentetic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentetreotide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentobarbital-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentosan-polysulfate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentostatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentoxifylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentoxiverine-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pentylenetetrazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/peramivir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perampanel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/percorten yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perfluorobutane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perflutren yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perforate-st-john-wort yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pergolide-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perindopril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perindopril-arginine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perindopril-erbumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/permethrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/perphenazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pertechnetate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pethidine-hydrochloride-5750 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenazon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenindione yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pheniramine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenobarbital yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenobarbital-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenolphthalein yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenoxybenzamine-hcl-5284441 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenprocoumon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phentermine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phentermine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phentolamine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenylalanine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenylbutazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenylephrine-bitartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenylephrine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenylpiracetam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenylpropanolamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenyltoloxamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenytoin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phenytoin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phloroglucinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pholcodine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phospholipid-dppc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phospholipid-azt yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phosphoric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/photofrin-porfimer-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phoxim yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/physostigmine-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pidotimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pilocarpine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pilocarpine-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pimecrolimus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pimobendan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pimozide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pimpinella-anisum-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pinaverium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pinazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pindolol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pioglitazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pioglitazone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pipamperone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pipecuronium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pipemidic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piperacillin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capromorelin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piperonyl-butoxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pipobroman yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piracetam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piretanide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pirfenidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pirlimycin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piroxicam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pitavastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pitofenone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pivampicillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pivmecillinam-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pizotifen-malate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/plantago-lanceolata-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/plerixafor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pirtobrutinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/podophyllotoxin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/policresulen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polidocanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polio-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polyestradiol-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polyethylene-glycol-monostearate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polymyxin-b-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polysorbate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pomalidomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ponatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/posaconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-alum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketobemidone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-chlorate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-dihydrogen-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-hydrogen-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-hydrogen-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-hydroxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-iodide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-perchlorate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/povidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/povidone-iodine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pralatrexate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pralidoxime-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pramipexole-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prasterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prasugrel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prasugrel-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pravastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/praziquantel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prazosin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prednicarbate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prednisolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prednisolone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prednisolone-sodium-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prednisone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pregabalin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pridinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prilocaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prilocaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/primaquine-diphosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/primidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/probenecid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/procainamide-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/procaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/procarbazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prochlorperazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/procyclidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/progesterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/proguanil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/proline-145742 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/promazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/promestriene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/promethazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/promethazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propacetamol-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propafenone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propantheline-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/proparacaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propentofylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propericiazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propiomazine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propiverine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propofol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propolis yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propoxyphene-napsylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propranolol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propyl-4-hydroxybenzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propylthiouracil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propyphenazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prucalopride-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prulifloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pseudoephedrine-7028 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pseudoephedrine-hydrochloride-9581 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrantel-pamoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrazinamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dha yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyridostigmine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyridoxal-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyridoxine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrilamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrilamine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrimethamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrithione-zinc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quad-tablet yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quadramet yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinapril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinidine-sulfate-hydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinine-sulfate-8549 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinupristine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rabeprazole-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rabies-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/racecadotril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/radium-223 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/raloxifene-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/raltegravir-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ramipril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ranitidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ranitidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ranolazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rasagiline-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/recombinant-human-growth-hormone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/regorafenib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/remifentanil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/repaglinide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/reserpine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/resveratrol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/retapamulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rhamnus-purshianus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rhepo yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rhodiola-rosea-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rhubarb yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ribavirin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ribitol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/riboflavin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tecovirimat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rifabutin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rifampicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rifamycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rifamycin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rifapentine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rifaximin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rilpivirine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rilpivirine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/riluzole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rimexolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rimonabant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/riociguat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/risperidone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ritodrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ritodrine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ritonavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rituximab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rivaroxaban yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rivastigmine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rivastigmine-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rizatriptan-benzoate-77997 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/robenacoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rocuronium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rofecoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/roflumilast yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rolapitant-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/romifidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ropinirole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ropinirole-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ropivacaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rose-hip-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rosiglitazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rosiglitazone-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefovecin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rosuvastatin-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rosuvastatin-zinc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rotigotine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/roxithromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orgalutran yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rubidium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucosamine-sulfate-sodium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rufinamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rupatadine-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rutin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ruxolitinib-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sacituzumab-govitecan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sacubitril-valsartan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/safinamide-methanesulfonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/salbutamol-sulphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/salicylamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/salicylic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/salmeterol-xinafoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/salvia-officinalis-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sapropterin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/saquinavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/saquinavir-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elacestrant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/saxagliptin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/saxagliptin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/s-benzoylmercaptoacetyltriglycine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/scopolamine-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/secnidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selamectin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selegiline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selenium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selenium-sulfide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selexipag yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/semaxanib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sennosides yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/septrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/serenoa-repens yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/serine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sermorelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/serratiopeptidase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sertaconazole-nitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sertindole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sertraline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sevelamer-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sevelamer-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sevoflurane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sibutramine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sifalimumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sildenafil-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/silodosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/silver-sulfadiazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/silybum-marianum-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/silymarin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/simeprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/simethicone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/simvastatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sirolimus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sitagliptin-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/soberol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atomoxetin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-dihydrogen-phosphate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-dihydrogen-phosphate-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-ferric-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-fluoride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-acetate-trihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-alginate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-ascorbate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-bicarbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-butyrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-carbonate-monohydrate-2735133 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-cromoglicate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-fluoride-18f yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-fusidate-23672955 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-glycerophosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-hyaluronate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-hydrogen-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-hydrogenphosphate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-hydroxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-hypochlorite yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-iodide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-iodide-131 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-iron-edta yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-lauryl-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-lauryl-sulfoacetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-mefenamate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-molybdate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-nitrite yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-nitroprusside yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-oxybate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-phenylbutyrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sotorasib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-picosulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-polystyrene-sulfonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-propionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-pyrophosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-selenite yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-tetradecyl-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-thiosulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-tripolyphosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-valproate-16760703 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sofosbuvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sofosbuvir-velpatasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/solifenacin-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/somatostatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/somatropin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sars-cov-2 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sorafenib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sorbitol-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sotalol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/soybean-oil-sterols-phytosterols yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/deutivacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/spectinomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/spectinomycin-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/spiramycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/spironolactone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/stannous-chloride-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/stavudine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/stiripentol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/streptokinase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/streptomycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/streptozocin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/strontium-chloride-sr-89 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/strontium-ranelate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/strontium-89-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/succimer yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/succinylcholine-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sucralfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sufentanil-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glycrrhizin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sugammadex-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulbactam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulbactam-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulbutiamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfacetamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfacetamide-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfachlorpyridazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfadiazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfadimidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfadoxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfamethizole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfamethoxazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfanilamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfasalazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfinpyrazone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfogaiacol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfur-hexafluoride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulindac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulodexide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulpiride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sultamicillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulthiame yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sultopride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sumatriptan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/porcine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/suncholin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sunitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daunorubicin-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/suxamethonium-chloride-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tacalcitol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tacrolimus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tadalafil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tafamidis yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tafamidis-meglumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tafluprost yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tamoxifen-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tamsulosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tannins yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tapentadol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tasimelteon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/taurine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/taurolidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tauroursodeoxycholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tazarotene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tazobactam-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tc-choletec yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/techneplex yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/technetium-99mtc-methylenediphosphonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/technetium-tc-99m-sestamibi-usp yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/technetium-99 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/technivie yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tegafur yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teicoplanin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telaprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telavancin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telbivudine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telithromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telmisartan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/temazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/temozolomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/temsirolimus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenofovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenofovir-alafenamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenofovir-disoproxil-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenofovir-disoproxil-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenoxicam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terazosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terazosin-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terbinafine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terbinafine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terbutaline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terbutaline-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teriflunomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teriparatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teriparatide-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/terpin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/testosterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/testosterone-cypionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/testosterone-enanthate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/testosterone-propionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/testosterone-undecanoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetanus-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetrabenazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetracaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetracaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetracosactide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetracycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetracycline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetrahydrocannabinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetrahydrofurfuryl-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetrahydrozoline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetrofosmin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thalidomide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thallium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thallium-201-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/theophylline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/theryttrex yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiamine-mononitrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiamphenicol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiethylperazine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiocolchicoside yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thioguanine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiopental-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thioridazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thiotepa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thrombin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thyme yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thyme-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thymol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thymopentin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thyrotropin-releasing-hormone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiagabine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiamulin-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tianeptine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tianeptine-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiapride-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiaprofenic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tibolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ticagrelor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ticlopidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tigecycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tildipirosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tilmicosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tilmicosin-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiludronic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/timolol-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tinidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tioconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiopronin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiotropium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tipiracil-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tipranavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiratricol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tirilazad yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tirofiban yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/titanium-dioxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tizanidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tobramycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tobramycin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/toceranib-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tofacitinib-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tolcapone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tolfenamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tolnaftate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tolperisone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tolterodine-tartrate-443878 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/toltrazuril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tolvaptan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/topiramate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/topotecan-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/toremifene-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/torsemide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trabectedin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tramadol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trametinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trandolapril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tranexamic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tranylcypromine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trapidil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trastuzumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/travoprost yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trazodone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/treosulfan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/treprostinil-sodium-6918140 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tretinoin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triamcinolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triamcinolone-acetonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triamcinolone-diacetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triamterene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triazolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tribulus-terrestris yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triclosan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trientine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triethanolamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triethanolamine-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trifluoperazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trifluridine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triflusal yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trilostane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trimebutine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trimegestone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trimetazidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trimethoprim yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trimipramine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tripelennamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triprolidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triptorelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triptorelin-pamoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trisodium-citrate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tromantadine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tropicamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tropisetron-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trospium-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trovafloxacin-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/troxerutin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tryptophan-6305 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tulathromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/turnera-diffusa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tylosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tylosin-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tylosin-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tylvalosin-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tyrothricin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ubidecarenone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ulipristal-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextrose-monohydrate-api-22814120 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/umeclidinium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/undecylenic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eprinomectin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/unii-38r1q0l1ze yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/unii-898723iqhq yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isometheptene-mucate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/unii-b7xf2td73c yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eliglustat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/molnupiravir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbetocin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sitagliptin-malate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dapivirine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/uracil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urapidil-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urate-oxidase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urea-c13 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urea-14c yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/uridine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urofollitropin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ursodeoxycholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urtica-urens-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ustekinumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexketoprofen-trometamol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valacyclovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valacyclovir-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valdecoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valerenic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valganciclovir-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valsartan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vancomycin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vandetanib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vardenafil-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/varenicline-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vecuronium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vedaprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vemurafenib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/venelex yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/venetoclax yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/venlafaxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/venlafaxine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/verapamil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/verapamil-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vernakalant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/verteporfin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vigabatrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vilanterol-trifenatate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vildagliptin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vinblastine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vincamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vincristine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vindesine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vinflunine-ditartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vinorelbine-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vinpocetine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vismodegib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-a yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-a-acetate-638034 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-a-palmitate-5280531 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-b1 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-b12-5311498 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-d yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-d3-5280795 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-e yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-e-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-k1 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitex-agnus-castus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/voclosporin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vorapaxar-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/voriconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vortioxetine-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eberconazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/walnut-leaf-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/warfarin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/water yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methoprene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluorodopa-f-18-56494 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/xenon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/xipamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/xylazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/xylometazoline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/xylometazoline-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/yttrium-radioisotopes yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zafirlukast yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zaleplon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zanamivir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zeaxanthin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ziconotide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ziconotide-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zidovudine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-acetate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-dichloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-oxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-sulphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vinburnine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/scopolamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ziprasidone-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ziprasidone-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quetiapine-hemifumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zofenopril-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zoledronic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zolmitriptan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zolpidem-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zonisamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zopiclone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zuclopenthixol-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zuclopenthixol-decanoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zuclopenthixol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bleomycin-sulphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phytin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/setmelanotide-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/4-amino-3-hydroxybutyric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acido-cromoglicico yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/afatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ajmalicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminum-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aminaftone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/barnidipine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bekanamycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bendazac yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benziodarone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bifidobacterium-longum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bornaprine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brivudine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromthalein yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/canrenoate-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefamandole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefditoren yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefodizima yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/netarsudil-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chromocarb-diethylamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clofoctol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloricromen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clothiapine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cocarboxylase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delorazepam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimefline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enoximone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenquizone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fenspiride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-sulfate-glycine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/follistim yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fotemustine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/frovatriptan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fusafungine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/heparan-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroconchinine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibopamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibuprofen-isobutanolammonium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/interferon-beta-1-14-human yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/isovaleric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/regadenoson-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/k-strophanthin-beta yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lanthanum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/letermovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lysozyme yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mepartricin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metadoxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methyl-aminolevulinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/micronomicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/miocamycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nepinalone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/niaprazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nicoboxil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxitropium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pasireotide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/picotamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piperilate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pirenoxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piribedil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piroxicam-cinnamate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pizotifen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pranoprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/proglumetacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propionylcarnitine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrrolnitrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/racephedrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/reboxetine-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rociverine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/roxatidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rufloxacin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/schembl892570 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/somatorelin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/spaglumic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfalene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tedelparin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telmesteine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiropramide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valpromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/baricitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/xibornol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avatrombopag-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zofenopril yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pegvisomant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cassia-angustifolia yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valerianae-radix yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glycosaminoglycan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ertugliflozin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/esketamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iobitridol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/molsidomine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nikethamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/turpentine-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromfenac-sodium-salt-sesquihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenofovir-alafenamide-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rilmenidine-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/histamine-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sotagliflozin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-sulfate-heptahydrate-62640 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rasagiline-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methyl-nicotinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzyl-nicotinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethyl-nicotinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminium-oxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metronidazole-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guaiazulene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorcyclizine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azilsartan-medoxomil-potassium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/milk-thistle-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fesoterodine-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flufenamic-acid-3371 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-lactate-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-sulfate-heptahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-carnosine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/filgrastim yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cabotegravir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glecaprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eltrombopag yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cabotegravir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ribociclib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/albiglutide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oclacitinib-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pradofloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pibrentasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eravacycline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bictegravir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nusinersen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delafloxacin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melphalan-flufenamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/filgotinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/semaglutide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delafloxacin-meglumine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delamanid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/disodium-folinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/asparagine-l-6267 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-alanine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/infliximab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/adalimumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/coagulation-factor-viii yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/senega yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/opium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lavandula-angustifolia yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gentian yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/arnica-montana yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epsilon-acetamidocaproic-acid-zinc-salt yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avibactam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/antazoline-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-glycerophosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/netarsudil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ozanimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/siponimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/midostaurin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ampicillin-benzathine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/coagulation-factor-ix-recombinant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/antazoline-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tirzepatide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etifoxine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/myrtecaine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/resorcinol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/butafosfan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxyclozanide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flunixin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hesperidin-methylchalcone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/umifenovir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cyromazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/velpatasvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-gluconate-excipient yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cimicoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/suxibuzone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-lactate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenofovir-disoproxil-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/macimorelin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/macimorelin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/grapiprant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/duvelisib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/acalabrutinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abemaciclib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brigatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naldemedine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telotristat-etiprate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telotristat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etelcalcetide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fexinidazole yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/talazoparib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/talazoparib-tosylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dibrompropamidine-isetionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/propamidine-isetionate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ruscogenin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lorlatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apalutamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/migalastat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prucalopride-usan-inn yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methenolone-enanthate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nandrolone-laurate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tirofiban-hydrochloride-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/follitropin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/denosumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/interferon-beta-1b yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aflibercept yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etanercept yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/drotrecogin-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nivolumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pembrolizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/secukinumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/baloxavir-marboxil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/protamine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tucatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/favipiravir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/momelotinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lysozyme-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-zirconium-cyclosilicate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dacomitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/upadacitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/risedronate-sodium-4194514 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brensocatib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/larotrectinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dasiglucagon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inotersen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gamma-aminobutyric-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chondroitin-sulfate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tezacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/neratinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/patiromer yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-dicloxacillin-23667628 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/monepantel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosfomycin-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rosin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fumagillin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/raltitrexed yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tigilanol-tiglate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cocarboxylase-tetrahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/peg-l-asparaginase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tritriacontanoic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/atezolizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daratumumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/binimetinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/axicabtagene-ciloleucel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/voretigene-neparvovec yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tisagenlecleucel yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/encorafenib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dupilumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quizartinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brentuximab-vedotin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ec-604-138-8 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erenumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/evolocumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brodalumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/durvalumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dexborneol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amino-acids-mixture yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/telotristat-ethyl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alanyl-glutamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emicizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teplizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bempedoic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivosidenib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/obinutuzumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/etrasimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lipase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pegvaliase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selinexor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lonafarnib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucarpidase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abciximab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alemtuzumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alirocumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avelumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/defibrotide-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dulaglutide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eculizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ipilimumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ixekizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omalizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/panitumumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pertuzumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ranibizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/romosozumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tocilizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vedolizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amifampridine-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lurbinectedin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ataluren yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avapritinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/remdesivir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/haemophilus-influenzae-type-b yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/relugolix yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tepotinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/navelbine-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vinflunine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/txonsemukvzuon-syvfvgefsa-n yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aldosterone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emoxypine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/voxelotor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/parathyroid-hormone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/darolutamide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosnetupitant-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ingavirin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactitolum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/opicapone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tildrakizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/burosumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sitagliptin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fosinoprilat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fruquintinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/roxadustat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tedizolid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zolazepam-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vadadustat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chymotrypsin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/padeliporfin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethyl-noradrianol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fostamatinib-disodium-hexahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pixantrone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nifurtimox yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meropenem-and-vaborbactam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tivozanib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guselkumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dinutuximab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omaveloxolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rucaparib-camsylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethiodized-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/solriamfetol-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epoetin-beta yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benralizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lebrikizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diroximel-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tribenoside yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/horse-chestnut-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selumetinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/asfotase-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nebicina yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ocrelizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lusutrombopag yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maribavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/human-rho-d-immune-globulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thrombin-bovine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/streptodornase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hepatitis-b-immune-globulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-phosphate-dibasic-trihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefiderocol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/enisamium-iodide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sarolaner yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sarilumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/naldemedine-tosylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clonixin-lysine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cypermethrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mogamulizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fremanezumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/galcanezumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pegloticase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olaratumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ramucirumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibalisumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levalbuterol-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eptinezumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alpelisib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bykomcyin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/momelotinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/patisiran yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vestronidase-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyrvinum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/doravirine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capmatinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/risdiplam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/orkambi yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elosulfase-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/flortaucipir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hsdb-8173 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/saccharomyces-boulardii yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactobacillus-acidophilus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactobacillus-rhamnosus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactobacillus-plantarum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lactobacillus-gasseri yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bifidobacterium-infantis yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/entrectinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vonicog-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dimorphone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lonapegsomatropin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/petrolatum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/paraffin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/certolizumab-pegol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vibegron yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/leuprolide-mesylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferric-maltol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ibritumomab-tiuxetan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avacopan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mirvetuximab-soravtansine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/desvenlafaxine-benzoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/rezafungin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/damoctocog-alfa-pegol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fedratinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imetelstat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gilteritinib-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alpha-amylase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/barnidipine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/anzemet-hydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/levomepromazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loprazolam-mesilate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/metamizole-magnesium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethylmorphine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxocobalamin-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abatacept yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vosoritide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valoctocogene-roxaparvovec yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cerliponase-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/human-c1-esterase-inhibitor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lanadelumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-asparagine-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/idursulfase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/albutrepenonacog-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sulfiram yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/asciminib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxomemazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/canakinumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moxetumomab-pasudotox yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caplacizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aldesleukin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/patiromer-sorbitex-calcium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tenecteplase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dornase-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lazertinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lixisenatidum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elotuzumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pyronaridine-tetraphosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aviptadil-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lasmiditan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capivasertib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/almagate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/citrulline-malate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/blinatumomab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-tyrosine-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/estetrol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calendula-officinalis yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ginkgo-biloba yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bibrocathol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tilia-cordata-miller yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetraria-islandica yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/verbena-officinalis-l yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/palivizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glasdegib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tislelizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vamorolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delta-l-alpha-aminoadipoyl-l-cysteinyl-glycine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/loncastuximab-tesirine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/natalizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/maralixibat-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aprocitentan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elafibranor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dostarlimab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/menthyl-isovalerate-119900 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethyl-2-bromoisovalerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/emoxypine-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/quinax yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-potassium-aspartate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/diosmectite yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/arginine-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phosphatidylcholine-18-0-18-2w6 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methyl-isovalerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mebhydrolin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polatuzumab-vedotin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pine-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sesame-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ac1ofct7 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hop-oil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/menthyl-isovalerate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clodronic-acid-disodium-salt yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lefamulin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teduglutide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trifarotene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/golimumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inclisiran yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/toripalimab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/efgartigimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/delgocitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sutimlimab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mavacamten yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polyferon yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tabelecleuce yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tiletamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ravulizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ivacaftor-tezacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cenegermin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/human-alpha-1-proteinase-inhibitor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alteplase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/theophylline-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/halofuginone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/luspatercept yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sotatercept yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tirbanibulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/artemisiae-argyi-folium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cenobamate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ajmaline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/morclofone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ipecacuanha-liquid-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/teprotumumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manganese-ii-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrocholinatum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/adagrasib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zinc-ii-gluconate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/l-arginine-l-aspartate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lutetium-177 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erdafitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inotersen-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tagraxofusp yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dermatophagoides-pteronyssinus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/apis-mellifera-venom yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dermatophagoides-farinae yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fibrinogen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imiglucerase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/coagulation-factor-x yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/coagulation-factor-vii-human yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/meningococcal-polysaccharide-vaccine-group-c yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tetanus-immunoglobulin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/agalsidase-beta yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/von-willebrand-factor-human yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lutropin-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alpha-l-idosiduronase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/peginterferon-alfa-2a yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/eftrenonacog-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nonacog-beta-pegol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brolucizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnetite-fe3o4 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/danaparoid-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/polyhexanide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/choriogonadotropin-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/moroctocog-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/thyrotropin-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bicisate-dihydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/n99027v28j yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/voxilaprevir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indoxacarb yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tauroselcholic-acid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/simoctocog-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lotilaner yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/azedra yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/darbepoetin-alfa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aluminium-hydroxide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bismuth-oxide-bi2o3 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cetalkonium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/d-histidine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/d-valine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/328-39-2 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dantrolene yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chloroethane yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glasdegib-maleate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manganese yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/molybdenum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/obidoxime-chloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/monydrin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/leucovorin-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hypromellose-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/silver-ion yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferric-derisomaltose yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-aspartate-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/avibactam-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/osaterone-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bismuth-potassium-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mivacurium-cation yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vernakalant-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/linzagolix yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trypsin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/heme yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ethyl-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cfix yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzathine-penicillin-g-15232 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iron-bis-d-gluconato-kappao1-kappao2 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fucoidan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iodide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloxacillinum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/triamcinolone-hexacetonide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/silicon-dioxide-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ketoprofen-lysinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pretomanid yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piperaquine-phosphate-174478 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-pantothenate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sacubitril-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-sulfate-heptahydrate-62662 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pemigatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/relebactam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/amorolfine-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/abrocitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oxytetracycline-dihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zuranolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inotuzumab-ozogamicin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zanubrutinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/proximetacainum yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylglucamine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/bictegravir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vimseltinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbocysteine-lysine-134128 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/repotrectinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tafasitamab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/botulinum-toxin-type-a yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cemiplimab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mexazolam yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fezolinetant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/siponimod-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/indacaterol-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tromethamine-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/elexacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ripretinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/oteracil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gimeracil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/prasugrel-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ritlecitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/remimazolam-besylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vitamin-e-tpgs-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urea-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lenacapavir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/norfenefrine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cinitapride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/benzyl-alcohol-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/carbopol-940-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/policosanol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gelatin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ginseng-extract yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clostridium-difficile-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fidanacogene-elaparvovec yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/multivalent-group-b-streptococcus-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/marstacimab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/staphylococcus-aureus-4-antigen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trastuzumab-emtansine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tremelimumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorprothixene-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dosulepin-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tisotumab-vedotin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pralsetinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/danicopan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inebilizumab yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/calcium-saccharate-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-perhydrol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dapagliflozin-propanediol-monohydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sepiapterin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ganaxolone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/selpercatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pitolisant-hydrochloride-11551689 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fipronil yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-hydroxyquinoline-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/futibatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sitaxentan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cefiderocol-sulfate-tosylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/capmatinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cedazuridine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/niraparib-tosylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ifx-1 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ponesimod yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vericiguat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mitapivat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/resmetirom yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pegcetacoplan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vorasidenib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/menotropins yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ropeginterferon-alfa-2b-86278347 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/manganese-carbonate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/methylprednisolone-aceponate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/icosapent-ethyl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/guarana yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/olive yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penicillin-v-benzathine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/5-hydroxy-tryptophan-439280 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/phosphorus yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mercuric-sulfide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imepitoin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/aloe-vera yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydrostreptomycin-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/esflurbiprofen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/germanium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydrotalcite yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lanolin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ropocamptide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mavacoxib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadolinium-oxide-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/collagen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/alimemazine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/belzutifan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chromium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/foscarbidopa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/foslevodopa yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nirmatrelvir yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/trientine-tetrahydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ferrous-succinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sebetralstat yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/talc-api yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lutetium-177-vipivotide-tetraxetan yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/timothy-pollen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper-sulphate-pentahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imlunestrant yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/mono-propylene-glycol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/erythropoietin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cloperastine-fendizoate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/caprylic-capric-triglyceride-93356 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dextropropoxyphene-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/berotralstat-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gefapixant-citrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/milrinone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/piperacillin-tazobactam-23724843 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/disodium-pamidronate-pentahydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/nirogacestat-hydrobromide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iptacopan-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/zilucoplan-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/riboflavin-5-phosphate-sodium-23666409 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/seladelpar-lysine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vanzacaftor yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/clarithromycin yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluocortolone-caproate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fluocortolone-pivalate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-dna yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/butenafine-hydrochloride-443867 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/epinastine-hydrochloride-157313 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/hydroxyethyl-salicylate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/imidapril-hydrochloride-5485193 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/melperone yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sonidegib-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/potassium-phosphate-24450 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/edetate-calcium-disodium-8759 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/magnesium-trisilicate-44144413 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/urokinase yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dihydrocodeine-hydrogen-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/sodium-levofolinate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/pseudoephedrine-sulfate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/iron-iii-hydroxide-polymaltose-complex yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/copper-tetramibi-tetrafluoroborate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/cucurbita-pepo yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/butorphanol-tartrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/chlorobutanol-hemihydrate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/omega-3-acid-ethyl-esters-90 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glucagon-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/inavolisib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/daridorexant-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/linzagolix-choline yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/gadopiclenol yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/y27632 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tapentadol-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/volanesorsen yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/fructose-1-6-bisphosphate-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/glutathione-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/penethamate-hydriodide yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/human-papillomavirus-vaccine yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/osilodrostat-phosphate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/brilliant-green yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/valerian-officinalis yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/givinostat-hcl yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/difelikefalin-acetate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/ilunocitinib yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/vatinoxan-hydrochloride yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/tegomil-fumarate yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/dl-carnitine-hydrochloride-9794197 yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/lenacapavir-sodium yearly 0.7 https://www.pharmacompass.com/eu-ctd-dossier-marketing-authorisation/menbutone yearly 0.7